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The role of tumor cell chemosensitivity test in second-line or third-
line chemotherapy in non-small cell lung cancer
Jung, Maan-Hong; Lee, Eun-Young; Park, Eun-Ho; Oak, Chul-Ho; 
Jang, Tae-Won 
Internal Medicine, Gospel Hospital, Kosin University, Busan, Korea
Background: In treatment of advanced non-small cell lung cancer, the 
effect of chemotherapy is limited and unpredictable. Especially in cases 
of recurrent or relapsed tumor, the choice of regimen is very restricted. 
This study was to determine whether the sensitivity test of chemothera-
peutic agents is valuable in choosing the drugs of the second-line or 
third-line treatment in the advanced non-small cell lung cancer.
Methods: In 11 patients, resistant to or relapsed after the ﬁrst-line or 
second-line chemotherapy, we got the tumor cells by the nine neck 
nodes or two bronchoscopic biopsies and did chemosensitivity test by 
the adenosine triphosphate-based chemotherapy response assay meth-
ods. The drugs tested were cisplatin, carboplatin, paclitaxel, docetaxel, 
gemcitabine, vinorelbine and irinotecan. We regarded the drug is sensi-
tive in cases the cell death rate was above 30%, and chose two drugs of 
higher cell death rates as chemotherapeutic agents. After two cycles of 
chemotherapy, the response was evaluated.
Results: The mean age of the patients was 54.9 year, and one patient 
was excluded in the ﬁnal analysis because the secondary tumor was 
proved as small cell lung cancer. Five patients were for the second-line 
and another ﬁve were for the third-line chemotherapy. Six tumors were 
sensitive to 3 drugs, 2 tumors were to two, and another two were to one 
agent. Cisplatin, gemcitabine, vinorelbine and irinotecan were sensitive 
in 5 cases respectively. Docetaxel was sensitive in 3 cases, paclitaxel 
and carboplatin were sensitive in 2 cases respectively. Regardless of the 
previous treatment, cisplatin kept the sensitivity in 4 of 8, gemcitabine 
in 2 of 3, and docetaxel in 1 of 3 cases. Complete response was found 
in 2 of 8 evaluable patients, and partial response was in 3, stable in 1, 
and disease progressed in 2 cases.
Conclusions: In cases of recurrent or resistant non-small cell lung can-
cer, chemosensitivity test would provide another options in choosing 
the chemotherapeutic agents. 
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BCL-2, BCL-x
L
, Survivin and P53 protein expression and response 
to the chemotherapy with cisplatine and etoposide in non-small cell 
lung cancer
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Background: The identiﬁcation of molecular markers useful for che-
motherapy response assessment may help in treatment optimization of 
selected groups of patients that will beneﬁt from the therapy and help to 
improve the therapy results. Markers that would be useful for predic-
tive factors assessment in NSCLC are under investigation.
The aim of the study: Estimation of response to chemotherapy depend-
ing on BCL-2, BCL-x
L
, Survivin and P53 protein expression.
Material and Methods: The group of 60 consecutive patients that 
were admitted to The Oncology Center of Lublin Land and to Depart-
ment of Thoracic Surgery Medical University of Lublin was examined. 
The stage according to TNM was as follows: IIB - 26 cases (43,3%), 
IIIA - 34 cases (56,7%). Patients were treated with chemotherapy 
before planned surgery according to the schedule: cisplatin 30 mg/m2 
plus etoposid (PE) 100mg/m2 for three consecutive days, every 21 
days. The response to the therapy according to WHO was estimated. 
Protein expression was estimated by means of immunohistochemistry 
on parafﬁn tumor samples taken during surgery (the cut of was set on 
10% of positive cells). 
Results: Expression of BCL-2, BCL-x
L
, Survivin and P53 proteins was 
found in 20%, 81,7%, 90% and 53,3% of cases, respectively. The per-
centage of positive cells (positive cytoplasmic or nuclear signal) in 500 
tumor cells was estimated by semiquantitive method. Statistical analy-
sis showed signiﬁcant differences only in BCL-x
L
, and Survivin protein 
expression in response to chemotherapy. In patients that responded to 
the therapy we found less cells showing protein expression (p<0,05). 
There was no statistical signiﬁcant correlation between median P53 
protein expression and response to the chemotherapy, however low 
median per cent value of P53 positive cells was observed in patients 
that responded to the therapy.
Conclusion: High BCL-x
L
, and Survivin protein expression in tumor 
cells was found to be an important marker of lack of clinical response 
to the chemotherapy
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Impact of gender on median overall survival (MOS) in patients 
with advanced non-small cell lung cancer (NSCLC) treated with 
platinum-based chemotherapy- Single center experience
Khodadad, Kian1 Zakeri, Azadeh2 Masjedi, Mohammad R.3 Padyab, 
Mojgan4 Emami, Habib4 
1 Thoracic Oncology Dept., National Research Inst. of TB & Lung 
Disease, Tehran, Iran 2 Pharmaclogy Dept., National Research Inst. 
of TB & Lung Disease, Tehran, Iran 3 Pulmonary Dept., National Re-
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Introduction: There is a debate on the impact of sex on survival of 
patients with advanced NSCLC. We retrospectively evaluated whether 
or not sex affects median overall survival (MOS) in patients with 
advanced NSCLC treated with 2nd or 3rd generation platinum-based 
regimens.
Patients and Methods: 230 patients with advanced NSCLC (un-
resctable IIIA/IIIB/IV) treated with 2nd or 3rd generation platinum-
based chemotherapy was retrospectively analyzed for the impact of 
gender differences on MOS. Confounding factors (i.e. median age, 
stage and pathology) were also evaluated in both sexes.
Results: 181 men and 49 women were included in this analysis. There 
was no statistically signiﬁcant difference in stage distribution (i.e. 
IIA/IIIB/IIIBw+IV) in both sexes (P=0.2). The difference in pathologic 
subtypes (undiff. NSCLC, Squam., Adenoca.) was statistically signiﬁ-
cant between women and men (15.1/9.4/75.5% and 25.6/31.8/42.6, 
respectively) (P =0.1/0.001/0.001). Mean age was 53.2 ± 11 in women 
and 59.7 ±11.7 in men (P<0.001). Although the median survival time 
was longer in women but it was not statistically signiﬁcant (13.7 m vs 
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10.3 m, P= 0.14). Response rate was 32.7% and 38.7% in women and 
men, respectively (P=0.4).
Conclusions: Based on this study the MOS was not statistically sig-
niﬁcant between women and men with advanced NSCLC treated with 
platinum based chemotherapy. Differences in pathologic subtype and 
mean age may translate this ﬁnding. To elucidate the impact of sex on 
MOS in patients with advanced NSCLC we need further well balanced 
studies. 
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Docetaxel-induced interstitial pneumonitis (DIIP) in non-small cell 
lung cancer patients
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Korea, Suwon, Korea
Background: Docetaxel is a taxene anticancer drug with activity 
against a broad range of cancers. Pulmonary toxicity is a well-known 
complication observed with several anticancer drugs. But, interstitial 
pneumonitis as a toxicity of docetaxel is very rare.
Methods: A total of 53 patients with non-small cell lung cancer who 
received chemotherapy including docetaxel from January 2006 to 
December 2006 were analyzed retrospectively. 
Results: 9 out of 53 patients (17.0%) showed newly developed ground 
glass opacity with/without consolidation or reticular density on fol-
low up chest CT scans during docetaxel therapy. The lesions were 
not thought to be associated with disease progression or pulmonary 
infection. Majority of patients who showed newly developed abnormal 
CT ﬁndings consistent with interstitial pneumonitis had worsened or 
newly appeared dyspnea with deterioration of lung function of restric-
tive pattern. In association with the chemotherapy regimens, 7 out of 
9 patients with DIIP received weekly docetaxel (30-40mg/m2), and 
remaining 2 received non-weekly docetaxel(60-75mg/m2). Among 7 
patients who received weekly docetaxel, docetaxel only (30mg/m2) 
were 4, and docetaxel (40mg/m2) combined with cisplatin(35mg/m2) 
were 3. In association with the cumulative dose of docetaxel, below 
60mg/m2 was none, between 60 and 120 mg/m2 was 1, between 120 
and 240 mg/m2 were 4, and between 240 and 480mg/m2 were 4. The 
locations of abnormal radiographic ﬁndings were mainly peripheral (8 
out of 9) and upper lobe (7 out of 9). For the treatment of DIIP 4 out of 
9 patients received corticosteroid treatment, and all 4 patients showed 
symptomatic improvement. 
Conclusions: DIIP developed in increasing frequency as the cumula-
tive dose of docetaxel increased, especially with weekly regimen. 
Special concern should be given to the development of DIIP during 
docetaxel chemotherapy as its cumulative dose increases. DIIP should 
be included in differential diagnosis of newly developed radiographic 
abnormalities such as ground glass opacity or consolidation during 
docetaxel treatment especially if the lesion is peripheral and upper lobe 
predominant. For more clear clariﬁcation of DIIP, further prospective 
study of large scale is required.
P2-266 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
A phase II study of the combination chemotherapy of Docetaxel 
and Carboplatin in advanced non-small cell lung cancer
Kim, Ji-Ho; Ahn, Young Mi; Roh, Yong Ho; Nam, Seung-Hyun; Kim, 
Bong-Seog 
Seoul Veterans Hospital, Seoul, Korea
Background: To evaluate the efﬁcacy and safety of induction chemo-
therapy with docetaxel and carboplatin in advanced lung cancer.
Methods: Between January 2005 and January 2007, 54 patients were 
enrolled and evaluable. Patients were treated with Docetaxel 75mg/m3 
and Carboplatin AUC 5 on day 1 every 21 days.
Result: The median age was 62 (range 23-79) years old. Among the 
54 patients, 51 were male. Pathologically, 19 patients had adenocar-
cinoma, 19 patients had squamous carcinoma and 3 patients had large 
cell carcinoma. Complete responses (CR) were in 2(3.7%) patients and 
partial responses (PR) in 26(48.14%) patients. The overall response 
rate was 51.85% and the median response duration was 5 (range, 1 to 
12.7) months. The median progression-free survival was 10.5 (range, 
1.4 to 19.5) months. The median overall survival for all patients was 
14.8 (range, 1.4 to 23.8) months.
During a total 253 cycles, anemia greater than CTC grade 2 occurred 
in 51 cycles(20.15%), leukopenia occurred in 22 cycles(8.69%) and 
thrombocytopenia occurred in 19 cycles(7.5%). Non-hematologic 
toxicities were minor and easily controlled.
Conclusion: The combination chemotherapy of docetaxel and carbo-
platin has moderate efﬁcacy with acceptable toxicities in patients with 
advanced NSCLC.
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The efficacy and characteristics of palliative chemotherapy for 
elderly patients with advanced or recurrent non-small cell lung 
cancer
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Sunyoung Han, Hye Suk Lee, Se-Hoon Kim, Dong-Wan Kim, Young 
Hwan Heo, Dae Seog 
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Background: We conducted retrospective analysis to evaluate the efﬁ-
cacy and characteristics of palliative chemotherapy for elderly patients 
with advanced or recurrent non-small cell lung cancer(NSCLC).
Methods: Between Mar 2000 and Feb 2004, newly diagnosed chemo-
naïve patients with advanced or recurrent NSCLC were included. All 
patients were histologically or pathologically proven to be NSCLC, 
with performance status 0 to 2. Comorbidity was evaluated according 
to the Charlson’s comorbidity index. All patients received platinum-
based combination chemotherapy(containing paclitaxel or gemcitabine) 
as the ﬁrst-line treatment. The old age group was deﬁned as patients 
with 65 years or more of age.
Results: Total 404 patients were retrospectively analyzed. The number 
of patients in the young age and the old age group were 283(70%) and 
121(30%), respectively. The average number of total regimens(2.31 of 
old age vs. 2.81 of young age, respectively;p<0.001) and cycles(8.78 
vs. 10.69, p=0.006) per head were signiﬁcantly less in the old age 
group than in the young age group. Average administered doses of 
paclitaxel(119.3 vs. 137.4 mg/m2, p<0.001) and gemcitabine(1962.1 vs. 
2216.7 mg/m2, p<0.001) per cycle were lower in the old age group than 
